37394 Federal Register / Vol. 65, No. 115 / Wednesday, June 14, 2000 / Notices

Dated: June 8, 2000.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention.

[FR Doc. 00–14949 Filed 6–13–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 00146]

Cooperative Agreement With the

Kenya Medical Research Institute;

Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announces the

availability of funds for fiscal year (FY)

2000 for a cooperative agreement

program with the Kenya Medical

Research Institute (KEMRI) to conduct

complex research studies and related

activities to control and prevent malaria,

HIV/AIDS, and other diseases of public

health importance in Kenya. CDC is

committed to achieving the health

promotion and disease prevention

objectives of ‘‘Healthy People 2010’’, a

national activity to reduce morbidity

and mortality and improve the quality

of life. This announcement is related to

the focus areas of HIV and

Immunization and Infectious Diseases.

For the conference copy of ‘‘Healthy

People 2010’’, visit the internet site

http://www.health.gov/healthypeople.

The objectives of this proposal are:

1. To assist KEMRI in the conduct of

field and laboratory research on

important human infectious diseases

prevalent in Kenya with an emphasis on

malaria and HIV.

2. To improve the training of students

and public health professionals in basic

and applied public health research and

the training of students and other

professionals in the areas that provide

support to research efforts such as data

and financial management.

3. To strengthen KEMRI institutional

capacity to conduct research and

training in public health.

4. To incorporate the results of

research into operational disease

prevention and control programs in the

Republic of Kenya and insure sharing of

expertise and research findings with

other nations.

5. To determine national priority

areas and develop human resources

focused on public health.

B. Eligible Applicants

Assistance will be provided only to

KEMRI. No other applications are

solicited. KEMRI is the most appropriate

and qualified agency to conduct the

activities specified under this

cooperative agreement because:

1. KEMRI is the only research

organization in Kenya that possesses the

requisite scientific and technical

expertise, the infrastructure capacity

and who has conducted longitudinal

malaria and related HIV research in

areas of high morbidity (20 years for

malaria and 10 years for HIV/AIDS).

These combined attributes make them

the only organization in Kenya capable

of effectively conducting the research

proposed for this cooperative

agreement.

2. A major operational unit of KEMRI

is located in western Kenya in an area

of extremely high level malaria and HIV

transmission, and thus is ideally located

to evaluate approaches to preventing

and controlling these public health

problems.

3. KEMRI was established through the

Science and Technology Act of the

Republic of Kenya and has a Board of

Management appointed by the Minister

of Health which is responsible for

overseeing all research and which has a

well-developed secretariat to provide

administrative and technical support to

research services.

4. KEMRI has been collaborating with

health agencies on priority infectious

disease research for over 20 years on the

grounds of the KEMRI facility both in

Nairobi and Kisumu. The KEMRI

Facility has experienced staff,

equipment, and facilities to support the

collaboration.

C. Availability of Funds

Approximately $657,000 is available

in FY 2000 to fund one award. It is

expected that $574,000 will be available

for malaria and infectious diseases and

$83,000 will be for HIV/AIDS. It is

expected that the award will begin on

August 1, 2000, and will be made for a

5-month budget period within a project

period of up to five years. The funding

estimate may change.

Continuation awards within an

approved project period will be made

on the basis of satisfactory progress as

evidenced by required reports and the

availability of funds.

Use of Funds

Indirect costs will not be provided on

HHS Grants to international or foreign

organizations where the grant is

performed entirely outside the territorial

limits of the United States.

D. Where to Obtain Additional

Information

If you have any questions after

reviewing the content of all documents,

business management technical

assistance may be obtained from: Juanita

D. Crowder, Grants Management

Specialist, Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention,

Room 3000, 2920 Brandywine Road,

Atlanta, GA 30341–4146, Telephone:

(770)488–2734, Email address:

jdd2@cdc.gov.

For program technical assistance,

contact: Sue Binder, M.D., Division of

Parasitic Diseases, National Center for

Infectious Diseases, Centers for Disease

Control and Prevention 1600 Clifton

Road, Mailstop F–22, Atlanta, GA

30333, Telephone: (770)488–7793,

Email address: sbinder@cdc.gov.

Dated: June 8, 2000.

Henry S. Cassell, III,

Acting Director, Procurement and Grants

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 00–14950 Filed 6–13–00; 8:45 am]

BILLING CODE 4162–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 00098]

Grant To Support Natural Products

Research on Phytomedicines at The

University of Mississippi; Notice of

Availability of Funds

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 2000

funds for a grant program to Support

Natural Products Research on

Phytomedicines at the University of

Mississippi.

B. Eligible Applicant(s)

Single Source

Assistance will be provided only to

the National Center for Natural Products

Research, Thad Cochran Research

Center, University of Mississippi. No

other applications are solicited. The

Conference Report accompanying Public

Law 106–113 (H.R. 3194), Consolidated

Appropriations Act, 2000, found at H.R.

Rep. No. 106–479, at 599 (1999)

specified these funds for the University

of Mississippi to establish a program to

identify candidate phytomedicines for

clinical evaluation.

Federal Register / Vol. 65, No. 115 / Wednesday, June 14, 2000 / Notices 37395

C. Availability of Funds

Approximately $1,823,000 is available

in FY 2000 to fund one award. It is

expected that the award will begin on or

about September 30, 2000 and will be

made for a 12-month budget period

within a project period of up to three

years.

D. Where To Obtain Additional

Information

Business management technical

assistance may be obtained from: Van A.

King, Grants Management Specialist,

Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention

(CDC), Announcement [00098], 2920

Brandywine Road, Room 3000, Atlanta,

GA 30341, Telephone Number (770)

488–2751, Email Address

vbk5@cdc.gov.

Program technical assistance may be

obtained from: Earl Ford, Division of

Nutrition and Physical Activity,

National Center for Chronic Disease

Prevention and Health Promotion,

Centers for Disease Control and

Prevention (CDC), 4770 Buford

Highway, MS K–26, Atlanta, GA 30341–

3724, Telephone Number (770)488–

6015, Email Address EFord@cdc.gov.

Dated: June 8, 2000.

Henry S. Cassell, III,

Acting Director, Procurement and Grants

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 00–14943 Filed 6–13–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 00104]

National Tuberculosis Controllers

Association; Notice of Availability of

Funds

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 2000

funds for a cooperative agreement

program for the National Tuberculosis

Controllers Association (NTCA). This

program addresses the ‘‘Healthy People

2010’’, priority area of Immunization

and Infectious Diseases.

The purpose of this program is to: (1)

Maintain an effective communication

capacity among the nation’s

tuberculosis (TB) control officials (TB

Controllers) and TB nursing

professionals; (2) to sustain a capacity

for coordinating the rapid,

comprehensive assessment of problems

and opportunities in the field of TB

prevention and control; (3) to maintain

the capacity to coordinate the

consultations and collaborations that

produce a front line perspective on the

fast moving programmatic, scientific,

and technological issues affecting the

goal of TB elimination; (4) to assist in

identifying TB training needs; and (5) to

continue the capacity for cataloging and

tracking the public and private assets of

the nation’s TB elimination effort.

B. Eligible Applicants

Assistance will be provided only to

the National Tuberculosis Controllers

Association (NTCA). No other

applications are solicited.

NTCA is the only organization that

has an established relationship with

state and local health department TB

prevention and control programs, access

to TB Controllers and TB nursing

professionals, and expertise which is

necessary to carry out the project. NTCA

is a unique organization because of the

technical expertise of its members,

especially relating to its application

amidst the complex and changing

environment of front line health care

delivery.

Note: Public Law 104–65 states that an

organization described in section 501(c)(4) of

the Internal Revenue Code of 1986 that

engages in lobbying activities is not eligible

to receive Federal funds constituting an

award, grant, cooperative agreement,

contract, loan, or any other form.

C. Availability of Funds

Approximately $150,000 will be

available in FY 2000 to fund this award.

It is expected that the award will begin

on or about September 30, 2000, and

will be made for a 12-month budget

period within a project period of up to

5 years. Funding estimates may change.

Continuation awards within an

approved project will be made on the

basis of satisfactory progress as

evidenced by required reports and the

availability of funds.

D. Where To Obtain Additional

Information

This and other CDC announcements

can be found on the CDC home page

Internet address—http://www.cdc.gov.

Click on ‘‘Funding’’ then ‘‘Grants and

Cooperative Agreements’’. An

application kit will be provided to

NTCA.

If you have questions after reviewing

the contents of all the documents,

business management technical

assistance may be obtained from: Carrie

Clark, Grants Management Specialist,

Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention,

Room 3000, 2920 Brandywine Road,

Atlanta, GA 30341–4146, Telephone:

(404) 488–2783, E-Mail Address:

zri4@cdc.gov.

For program technical assistance,

contact: John Seggerson, Office of the

Director, Division of Tuberculosis

Elimination, National Center for HIV,

STD, and TB Prevention, Mail Stop E–

10, Atlanta, GA 30333, Telephone: (404)

639–5328, E-Mail Address:

jjs1@cdc.gov.

Dated: June 8, 2000.

Henry S. Cassell, III,

Acting Director, Procurement and Grants

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 00–14948 Filed 6–13–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Disease, Disability, and Injury

Prevention and Control Special

Emphasis Panel (SEP): Research To

Strengthen Occupational Safety and

Health Surveillance, RFA OH–00–005

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following meeting.

Name: Disease, Disability, and Injury

Prevention and Control Special Emphasis

Panel (SEP): Research to Strengthen

Occupational Safety and Health Surveillance,

RFA OH–00–005.

Times and Dates:

9 a.m.–9:30 a.m., July 10, 2000 (Open).

9:30 a.m.–5 p.m., July 10, 2000 (Closed).

8 a.m.–Noon, July 11, 2000 (Closed).

Place: Embassy Suites, 1900 Diagonal

Road, Alexandria, Virginia 22314.

Status: Portions of the meeting will be

closed to the public in accordance with

provisions set forth in section 552b(c)(4) and

(6), Title 5 U.S.C., and the Determination of

the Associate Director for Management and

Operations, CDC, pursuant to Public Law 92–

463.

Matters to be Discussed: The meeting will

include the review, discussion, and

evaluation of applications received in

response to RFA–OH–00–005.

Contact Person for More Information:

Michael J. Galvin, Jr., Ph.D., Health Science

Administrator, Centers for Disease Control

and Prevention, National Institute for

Occupational Safety and Health, 1600 Clifton

Road, N.E., m/s D30 Atlanta, Georgia 30333.

Telephone 404/639–3525, e-mail

mtg3@cdc.gov.